论文部分内容阅读
目的探讨西妥昔单抗联合调强适形放射治疗(IMRT)治疗局部晚期鼻咽癌的临床疗效和安全性。方法选择青岛市肿瘤医院收治的100例局部晚期鼻咽癌患者的临床资料,随机分为观察组和对照组,观察组50例患者采用西妥昔单抗联合IMRT治疗,对照组50例患者采用IMRT治疗,比较两组患者的疗效。结果治疗后,观察组患者总有效率为92.0%,明显高于对照组患者的50.0%,差异有统计学意义(P<0.05);观察组患者治疗后1年生存率(75.0%)明显优于对照组(62.5%),差异有统计学意义(P<0.05);两组患者不良反应均较轻,差异无统计学意义(P>0.05)。结论采用西妥昔单抗联合调强适形放射治疗(IMRT)治疗局部晚期鼻咽癌疗效显著,有利于提高患者的生存率,值得临床推广和应用。
Objective To investigate the clinical efficacy and safety of cetuximab combined with intensity-modulated conformal radiotherapy (IMRT) in the treatment of locally advanced nasopharyngeal carcinoma. Methods The clinical data of 100 patients with locally advanced nasopharyngeal carcinoma admitted to Cancer Hospital of Qingdao City were randomly divided into observation group and control group. 50 patients in observation group were treated with cetuximab and IMRT, and 50 patients in control group IMRT treatment, the efficacy of the two groups were compared. Results After treatment, the total effective rate in the observation group was 92.0%, which was significantly higher than that in the control group (50.0%, P <0.05). The 1-year survival rate (75.0%) in the observation group was significantly better In the control group (62.5%), the difference was statistically significant (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion Cetuximab combined with intensity-modulated conformal radiotherapy (IMRT) for the treatment of locally advanced nasopharyngeal carcinoma has a significant effect, which is beneficial to improve the survival rate of patients and is worthy of clinical promotion and application.